Protoga
Protoga is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.
Protoga is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.
Protoga has raised $14.8M across 1 round. Its most recent round was a Series A of $14.8M in Aug 2026. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Protoga is featured in
Similar companies
Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications.
NewLine researches phage feed additives to prevent livestock infections.
Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research.
Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products.
Epigenic Therapeutics is a drug development company that develops gene modulation therapies through the regulation of epigenetic mechanisms.
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.
Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.
JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.
BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.
CND Life Sciences is committed to supporting patients with neurodegenerative diseases, offering the Syn-One Test® as a first-of-its-kind tool to detect and measure misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This test helps confirm synucleinopathies like Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company operates a CLIA-certified and CAP-accredited lab in Scottsdale, AZ, providing a convenient and accurate alternative for diagnosis through skin biopsies. Additionally, CND collaborates with biopharmaceutical companies to advance research in the field.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.